Thymosin Beta 4 5mg – Buy TB500 online

Thymosin Beta 4 5mg – Research Product Information

Thymosin Beta 4 5mg is a peptide-related product listed with the search term TB500. The stated quantity is 5mg. An important distinction should be checked before publication: full-length thymosin beta-4 (Tβ4) and the compound commonly marketed as TB-500 are not necessarily the same molecule. The product name alone does not confirm which one is supplied. This description therefore avoids treating the two names as interchangeable or claiming an unverified chemical identity.

The brand has not been specified, and no manufacturer documentation, product format, packaging details, purity figure or batch-testing information has been provided. Customers should be able to verify these details before making a purchasing decision.

Product overview

Thymosin beta-4 is a naturally occurring peptide found in mammalian tissues. It has been investigated in scientific research relating to cellular processes and tissue biology. TB-500 is a name commonly used for a synthetic fragment associated with thymosin beta-4. However, research on the full-length thymosin beta-4 molecule cannot automatically be treated as research on TB-500.

A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons specifically highlights this distinction and notes that evidence for TB-500 should not be assumed from studies of full-length thymosin beta-4. It also discusses limitations in human evidence and concerns about the identity and quality of commercially marketed products.

For this listing, the confirmed product information is limited to the name Thymosin Beta 4 5mg and the stated 5mg quantity. Whether the material is full-length Tβ4 or a TB-500 fragment must be established from the manufacturer’s specification or a suitable analytical document.

Why consider this product?

When evaluating a peptide research product, accurate identification and transparent specifications matter more than promotional claims. Customers should be able to understand what compound is being offered, how much is stated to be included and what supporting documentation is available.

Key considerations for this listing include:

• Stated quantity: The product name specifies 5mg.

• Compound identity: The exact molecular identity should be confirmed, particularly because Tβ4 and TB-500 are sometimes conflated.

• Research context: Thymosin beta-4 and related fragments appear in scientific literature, but the evidence must be assessed according to the specific molecule and study.

• Product transparency: Format, packaging, batch details and analytical documentation should be disclosed where available.

• Clear product positioning: Research-focused descriptions should not imply approved medical use or proven clinical outcomes.

No purity percentage, independent testing, Certificate of Analysis, manufacturing certification or specific packaging has been confirmed for this product. These details should not be assumed.

Research information

Thymosin beta-4 is a peptide that has been investigated in several areas of experimental biology. Research has examined its biological properties in laboratory and animal models, as well as selected clinical research involving specific formulations and applications.

TB-500 is commonly used commercially to refer to a shorter synthetic fragment related to thymosin beta-4. It is important not to assume that studies of the full-length peptide establish the properties, safety or effectiveness of the fragment. A 2026 scoping review found that the published evidence base is weighted towards preclinical work and that direct human evidence for TB-500 is limited.

Researchers can explore the scientific literature through PubMed’s thymosin beta-4 search and PubMed’s TB-500 search. These databases help readers distinguish studies by compound, formulation, experimental model and research question.

Quality and product transparency

A reliable product listing should make it possible to identify the supplied compound and review the available evidence supporting its stated specifications. For a product using both the terms thymosin beta-4 and TB500, the manufacturer’s identity statement is especially important.

Before publication, the supplier should confirm:

• Whether the material is full-length thymosin beta-4 or a TB-500 fragment.

• Whether a batch-specific Certificate of Analysis is available.

• Whether identity and purity testing have been performed and documented.

• The supplied format and packaging.

• Any manufacturer, batch or traceability information.

Peptide Depot should only advertise testing, purity, certifications or manufacturing standards where genuine supporting documents are available. No such claims are made here.

Buying with confidence in the UK

Customers considering peptide-related products should review the product identity, stated quantity, available documentation, supplier contact information and published delivery terms. Secure checkout and clear customer support information are also useful parts of a transparent buying experience.

UK regulatory requirements should be considered before a product is offered for sale. The MHRA guidance on supplying unlicensed medicinal products explains the framework for unlicensed medicines supplied for individual patients’ clinical needs. The Human Medicines Regulations 2012 set out the relevant legislation. Describing a product as research-only does not, by itself, establish that its sale or supply is lawful.

Important research-use notice

This listing is written for research-information purposes and does not present thymosin beta-4 or TB-500 as a medicine or treatment. It does not establish suitability for human or animal administration. The exact compound identity, intended purpose and UK regulatory status must be verified before the product is offered for sale.